Catalent, a contract drug manufacturing company, reassured customers that its proposed acquisition by Novo Nordisk’s parent company will not raise competitive concerns. Novo Holdings, the majority owner of Catalent, plans to sell three facilities to Novo Nordisk for $11 billion. The deal has prompted speculation about potential regulatory hurdles due to concerns about anti-competitive practices. Catalent is currently a subcontractor for manufacturing a widely prescribed weight loss drug, making it an attractive target for acquisition. The deal, announced in February, has raised questions about the implications of Novo Holdings controlling a major player in the pharmaceutical contract work industry.
Source link
Catalent tries to reassure customers about its deal with Novo Holdings
